Non-alcoholic steatohepatitis is liver inflammation and damage caused by an accumulation of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease. It leads to cirrhosis and an increased risk of liver failure and hepatocellular carcinoma in some cases. Global Non-Alcoholic Steatohepatitis Market will reach USD 9727.96 Million by 2023 from USD 4124.74 Million in 2018 with a CAGR of 13.04% during the period.
Growth by region
Asia-Pacific will experience growth with a high CAGR due to growth in diagnostic techniques, increasing prevalence of NASH, and development of healthcare infrastructure. North America held the largest market share owing to the prevalence of NASH and the presence of drugs in development.
Report Sample Request: https://www.trendsmarketresearch.com/report/sample/3995
Drivers vs Constraints
Rising cases of diabetes and obesity are the main drivers for the growth of the market. Growing demand for NASH therapies and rising prevalence of NASH are the factors driving the market. However, the lack of diagnostic technologies for NASH is hampering the growth of the market.
Place Direct Order Form @ https://www.trendsmarketresearch.com/checkout/3995/Single
Industry Trends and Updates
AstraZeneca has licensed IONIS-AZ6-2.5-LRx, a NASH drug from Ionis Pharmaceuticals, Inc. for $30 million.
Allergan acquired Tobira Therapeutics Inc. and Akarna Therapeutics Ltd., which provide Allergan with an off-the-shelf pipeline for the potentially lucrative NASH market.
Report Discount Request: https://www.trendsmarketresearch.com/report/discount/3995